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ABSTRACT   
Follow-up care is important for childhood cancer survivors to facilitate early detection and treatment of 
late-effects. We aimed to describe preferences for different organisational aspects and models of follow-
up care among Swiss childhood cancer survivors, and characteristics associated with preferences for 
different models. We contacted 720 survivors aged 18+ years, diagnosed with cancer after 1990 (age 0-16 
years), registered in the Swiss Childhood Cancer Registry (SCCR), and Swiss resident, who previously 
participated in a baseline survey. They received questionnaires to assess attendance and preferences for 
follow-up (rated on 4 point scales, 0-3). Clinical information was available from the SCCR. Survivors 
(n=314: response rate 43.6%; 47.8% still attended follow-up) rated clinical reasons for follow-up higher 
than supportive reasons (p<0.001). They rated checking for cancer recurrence (mean=2.78, SD=0.53) and 
knowing about risks for my children most important (mean=2.22, SD=0.83). They preferred to attend a 
children’s hospital (mean=1.94, SD=1.11), adult hospital (mean=1.86, SD=0.98) or general practitioner 
(mean=1.86, SD=1.01) rather than a central specialised late effects clinic (mean=1.25, SD=1.06, p<0.001), 
and be seen by paediatric (mean=2.24, SD=0.72) or medical oncologist (mean=2.17, SD=0.69). Survivors 
preferred decentralised clinic-based follow-up, rather than one central specialised late effects clinic. 
Survivors’ preferences should be considered to ensure future attendance. 
Keywords: oncology, survivors, aftercare, patient preference, organization 
 
INTRODUCTION 
Follow-up care is vital for many childhood 
cancer survivors due to the high risk of late 
effects (Geenen et al., 2007, Hudson et al., 2013, 
Oeffinger et al., 2006). Follow-up offers 
potential for early detection and treatment of late 
effects and an opportunity to offer age-
appropriate information about disease, treatment 
and a healthy lifestyle, practical advice about 
insurance, education or work, and psychosocial 
support (von der Weid and Wagner, 2003, 
Gianinazzi et al., 2014, Vetsch et al., 2015). 
Published guidelines describe risk-based follow-
up for childhood cancer survivors (Scottish 
Intercollegiate Guidelines Network (SIGN), 
2004, Stichting Kinderoncologie Nederland 
(SKION), 2010, Children's Oncology Group, 
2013), and evidence-based, risk-adapted 
examinations. Despite the potential advantages 
of follow-up, attendance is often low (Michel et 
al., 2011b, Rebholz et al., 2011, Essig et al., 
2012). 
 
Previous studies highlighted the importance of 
assessing survivors’ views and preferences about 
follow-up care (Aslett et al., 2007, Earle et al., 
2005, Michel et al., 2009) to ensure it is relevant 
to survivors and consequently associated with 
good attendance. However, little is known about 
survivors’ views of follow-up. They appear more 
interested in medical aspects of follow-up care 
such as checking for relapse, late effects and 
general health status, compared with gaining 
information about wider issues such as effects of 
cancer on employment or education, or health 
behaviour (Michel et al., 2009, Eiser et al., 
1996). Organisational issues such as waiting 
time or length of consultation influenced 
satisfaction with care (Absolom et al., 2006). 
 
Other work has addressed preferences for 
different models of follow-up care (e.g. 
continuation of care with the paediatric 
oncologist, transfer to adult clinic or general 
practitioner (GP), or follow-up by 
telephone/questionnaire). Most survivors were 
satisfied with the care they received (Eiser et al., 
1996, Michel et al., 2011a), and wished to 
continue this model of follow-up (paediatric or 
adult clinic) (Absolom et al., 2006, Michel et al., 
2009). Two qualitative studies concluded that 
GP follow-up was convenient but survivors were 
not confident about GPs knowledge about 
survivorship-specific care (Zebrack et al., 2004, 
Earle et al., 2005). However, most studies only 
included survivors attending follow-up 
appointments and therefore may not be relevant 
when considering views of survivors who do not 
attend follow-up care for whatever reason. 
 
We aimed to describe 1) preferences for different 
organizational aspects and models of follow-up 
care among Swiss childhood cancer survivors 
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(including both current attenders and non-
attenders to follow-up care), and 2) 
characteristics of survivors associated with 
preferences for different models of care. 
 
METHODS 
Sample and procedure 
The Swiss Childhood Cancer Registry (SCCR) is 
a population-based registry including all Swiss 
residents diagnosed before age 21 years with 
leukaemia, lymphoma, central nervous system 
(CNS) tumour, malignant solid tumour or 
Langerhans cell histiocytosis (Michel et al., 
2007, Michel et al., 2008). The Swiss Childhood 
Cancer Survivor Study (SCCSS) is a nationwide, 
long-term follow-up study of all patients 
registered in the SCCR who were diagnosed 
between 1976-2005 and survived for ≥5 years 
(Kuehni et al., 2012a).  
 
For the baseline survey, between 2007-2009, all 
survivors aged older than 16 years at study 
received an information letter about the study 
from their treating institution. They were asked 
whether or not they wished to participate, their 
address, or if they required the baseline 
questionnaire in another language (German, 
French, and Italian). Two weeks later, all 
survivors received a paper-based questionnaire 
(baseline) with a prepaid return envelope. Non-
responders received another questionnaire after 2 
months and then were contacted by phone if they 
did not respond.  
 
After approximately 3 years all participants who 
had completed the baseline questionnaire, were 
aged ≥18 years, and diagnosed with cancer at 
age ≤16 years between 1990-2005, received a 
follow-up questionnaire. Non-responders to this 
questionnaire were sent a reminder letter with a 
questionnaire and prepaid return envelope two 
months later. Because there were few Italian 
speaking participants, the second questionnaire 
was provided only in German and French. For 
the current study survivors whose parents 
completed the baseline questionnaire were 
excluded. 
 
Ethics approval was provided through the 
general cancer registry of the SCCR (The Swiss 
Federal Commission of Experts for Professional 
Secrecy in Medical Research) and a non obstat 
statement (the ethical committee did not object 
to the running of the study) was obtained from 
the ethics committee of the canton of Bern. 
Participants gave informed consent for the study 
by returning the completed questionnaire. 
 
The questionnaires 
The baseline questionnaire was based on those 
used in the US and UK childhood cancer 
survivor studies (Robison et al., 2002, Hawkins 
et al., 2008), and covered the following topics: 
quality of life, somatic health, current 
medication, health service utilization, 
psychological distress, health behaviour and 
socio-economic information. The focus of the 
follow-up questionnaire was follow-up care and 
psychological outcomes.  
 
Measurements 
Baseline questionnaire 
We assessed sex, migration background and self-
reported late effects. We coded participants as 
having a migration background if they were not 
Swiss citizens, were not born in Switzerland, or 
at least one parent was not a Swiss citizen. We 
asked if survivors experience late effects from 
cancer or treatment (yes/no). 
 
Follow-up questionnaire  
Outcome measures:  
Follow-up attendance: We asked survivors if 
they still attended follow-up care (a) “I regularly 
attend follow-up”, b) “I irregularly attend 
follow-up”, c) “Follow-up is completed but I 
visit my treating doctor when I have questions”, 
d) “Follow-up is completed and I never visit my 
former treating doctor”. We coded (a) and (b) as 
attenders [1], and (c) and (d) as non-attenders 
[0]. 
 
Reasons for follow-up (Michel et al., 2009): 
Survivors rated the importance of different 
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reasons for attending follow-up (0=“not at all 
important” to 3=“very important”). Factor 
analysis revealed two scales: supportive care (get 
information about late effects, talk to staff who 
understand what I've been through, get advice 
about how to keep healthy, receive psychological 
support, get advice about everyday things) and 
clinical care (check the cancer has not come 
back, get reassurance about health, help clinic 
staff learn more about late effects, get the best 
medical care). Cronbach’s alpha in our sample 
indicated a good internal consistency for both 
scales: supportive care: α=0.80; clinical care 
α=0.69. 
 
What is important during appointments: 
Survivors rated the importance of 10 
organisational aspects of follow-up appointments 
(0=“not at all important” to 3=“very important”): 
Competent staff, being taken seriously, 
relationship quality between doctor and patient, 
insurance reimbursement, doctor continuity 
across appointments, no long waiting times, 
regular appointments, short and efficient 
consultation, nurse continuity across 
appointments, meeting other survivors. 
 
What should be included in follow-up: We asked 
about the importance of four clinical aspects 
(check that cancer has not come back, screen for 
late effects, provide information on potential late 
effects, other medical follow-up) and eight 
general aspects of follow-up (risk of diseases for 
my children, psychological counselling, 
availability of alternative medicine, 
information/counselling about sexuality, 
information about education / job, exchange with 
other survivors, support in spiritual aspects of 
life, other offers). Each aspect was rated on a 4 
point scale (0=“not at all important” to 3=“very 
important”). 
 
Who should be involved in follow-up: Survivors 
rated how personally important it is that different 
medical and other specialists are involved in 
follow-up (0=“not at all important” to 3=“very 
important”): paediatric oncologist, general 
practitioner (GP), medical oncologist, fertility 
counselling, gynaecologist, endocrinologist, 
psychologist/psychiatrist, specialist nurse, 
radiotherapies, nutritional counselling, 
physiotherapist, geneticist, insurance 
counselling, social worker, career counselling, 
other specialist) 
 
Where should follow-up be provided: We asked 
survivors’ agreement (0=“don’t agree at all” to 
3=“completely agree”) about the place where 
they would like to attend follow-up: a) at the 
paediatric hospital, where they were treated, b) a 
hospital for adults, c) a central, specialised 
follow-up clinic, d) their GP. 
 
Preferences for models of follow-up care: We 
provided a short description of five different 
models of follow-up care: a) 
telephone/questionnaire based follow-up, b) GP 
follow-up, c) follow-up by paediatric oncologist 
who originally treated the patient, d) medical 
oncologist follow-up, e) hospital-based follow-
up by a multidisciplinary team (MDT). For each 
model we asked survivors if this kind of follow-
up would suit them, if they were afraid that 
health problems would not be detected, if they 
would not be satisfied with this kind of follow-
up, and if they thought that this kind of follow-
up was appropriate for their health (0=“don’t 
agree at all” to 3=“completely agree”). Two 
items were reverse coded such that a higher 
score indicated higher positive agreement for the 
respective model (0-3). We calculated the mean 
of the four items to indicate agreement with each 
model. For model e) we asked 4 additional 
items, which were analysed separately (I can 
contact all specialists I need, I can be referred to 
the right specialist, follow-up is less personal, I 
don’t know who is responsible for me). 
 
Socio-demographic characteristics and 
psychological distress: 
Psychological distress: We used the Brief 
Symptom Inventory-18 (BSI-18)(Derogatis, 
2000) and calculated scores for somatisation, 
depression, anxiety, and a Global Severity Index 
(GSI). Survivors rated how much they 
experienced each symptom during the 7 previous 
days on a 5-point scale (1=”not at all” to 
5=”extremely”). Scale scores were converted 
into T-scores (mean=50; standard deviation 
(SD)=10). We created a case-indicator 
specifying survivors with high distress (T≥57 on 
at least 2 scales or the GSI) (Zabora et al., 2001, 
Preferences for follow-up care   5 
 
Gianinazzi et al., 2013). Cronbach’s α in our 
sample indicated a good internal consistency for 
all three scales and the GSI(somatization: 
α=0.78; depression: α=0.90; anxiety: α=0.80; 
GSI α=0.91). Educational achievement was 
coded as primary (compulsory schooling), 
secondary (vocational training or high school 
degree), and tertiary education (college or 
university degree) (Kuehni et al., 2012b). 
Employment was coded as “employed”, “in 
education” or “not employed”. Partnership was 
coded as not having a partner vs. being in a 
partnership. Age at study was coded into ≤25 
years and >25 years. The language was coded 
into German and French.  
 
Data available from the SCCR 
Age at diagnosis was coded into 0-4 years, 5-9 
years, 10+ years. Time since diagnosis was 
coded into 5-9 years, 10-14 years, 15+years. 
Diagnoses were classified according to the 
International Classification of Childhood 
Cancer-3rd edition) (Steliarova-Foucher et al., 
2005). We recoded diagnoses into four major 
groups: leukaemia, lymphoma, CNS tumours 
and other solid tumours. Treatment was coded as 
surgery only, chemotherapy (without 
radiotherapy, may have had surgery), 
radiotherapy (may have had surgery and/or 
chemotherapy) and stem cell transplantation 
(SCT). Relapse and second malignancy were 
coded as yes/no. 
 
Analyses 
All analyses were performed using Stata 13.0 
(StataCorp, College Station, TX). Numbers for 
each outcome vary because not all participants 
answered all questions. We used descriptive 
statistics and chi2-test to compare participants 
and non-participants in the study. To analyse aim 
1 (preferences for different organizational 
aspects and models of follow-up care) we used 
means and proportions to describe different 
preferences for organizational aspects and 
models of follow-up care. Paired t-tests were 
used to compare the importance of clinical and 
supportive reasons, and as post-hoc test 
following Hotelling T-test for the comparison of 
more than two means. We used t-test and chi2-
test to analyse differences in preferences 
between attenders and non-attenders to follow-
up. To evaluate aim 2 (characteristics of 
survivors associated with preferences for 
different models of care), we used univariable 
and multivariable linear regression analyses 
using the mean satisfaction with each model of 
care as outcome. We ran separate regression 
analyses for each of the five described models of 
follow-up care. For multivariable regressions, we 
included all variables, which were significantly 
associated at p<0.05 in the univariable 
regressions for at least one of the follow-up 
models. 
 
RESULTS 
A total of 754 survivors were eligible for the 
follow-up questionnaire. We were able to contact 
720 of these, and 314 were included in the study 
(43.6%; Figure 1). Participants’ characteristics 
are described in Table 1. Participants were more 
likely than non-participants to be female, and to 
have received radiotherapy, but less likely to 
have had surgery only. 
1) Preferences for the organisation of follow-
up care 
Of the 314 responders, 150 (47.8%) reported 
they still attended follow-up (Table 1).  
Reasons for follow-up: Clinical reasons 
(mean=2.33, SD=0.58) were more important 
than supportive reasons (mean=1.61, SD=0.71; 
p<0.001; Figure 2). Most important reasons for 
survivors to return were to Check that cancer 
has not come back (mean=2.53, SD=0.80) and 
seek reassurance about health (mean=2.44, 
SD=0.72); least important were to receive 
psychological support (mean=1.30, SD=1.02) 
and get advice about everyday things 
(mean=1.21, SD=1.00). 
What is important during appointments: 
Survivors reported that competent staff 
(mean=2.74, SD=0.47) and being taken seriously 
(mean=2.70, SD=0.49) were most important to 
them during appointments (Figure 3), and 
significantly more important than the 
relationship quality (mean=2.51, SD=0.64; 
p<0.001). Nurse continuity across appointments 
(mean=1.43, SD=0.92) and meet other survivors 
(mean=0.89, SD=0.83) were least important. 
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What should be included? When asked about 
clinical aspects that should be included in 
follow-up survivors agreed that checking for 
cancer recurrence (mean=2.78, SD=0.53) was 
most important (Figure 3), more than screening 
for late effects (mean=2.67, SD=0.53; p=0.001) 
and gaining information on potential late effects 
(mean=2.63, SD=0.55; p<0.001). Knowing 
about risks for my children (mean=2.22, 
SD=0.83) was rated as most important among 
general aspects. The possibilities for interaction 
with other survivors (mean=0.95, SD=0.86) and 
getting advice on spiritual things were rated as 
not important (mean=0.42, SD=0.66). 
Who should be involved: Paediatric oncologist 
(mean=2.26, SD=0.96), general practitioners 
(mean=2.10, SD=0.99) and medical oncologist 
(mean=2.07, SD=0.95) were rated as most 
important to be included in follow-up (Figure 3). 
Other specialists or counselling options such as 
nutritional counselling (mean=0.99, SD=0.90), 
physiotherapist (mean=0.99, SD=0.88), 
geneticist (mean=0.97, SD=0.96), insurance 
counselling (mean=0.89, SD=0.92), social 
worker (mean=0.74, SD=0.83), and career 
counselling (mean=0.69, SD=0.83) were 
considered less important. 
Where should follow-up be provided: Survivors 
showed no preference for place of follow-up 
(Figure 3): children’s hospital (mean=1.94, 
SD=1.11), adult hospital (mean=1.86, SD=0.98) 
or GP practice (mean=1.86, SD=1.01; no 
significant difference: for all p>0.05). A central 
specialised late effects clinic was rated least 
acceptable (mean=1.25, SD=1.06; compared to 
the three other clinics: p<0.001). 
There was little difference in preferences for 
follow-up between attenders and non-attenders 
to follow-up (Online Table 1). Attenders 
reported slightly higher preference for clinical 
reasons for follow-up (p=0.014), to get the best 
medical care (p=0.009), and to talk to staff who 
understood what they had been through 
(p=0.008). They also valued regular 
appointments (p<0.001) and information about 
education or work (p=0.001) higher than non-
attenders. Attenders rated presence of 
endocrinologists (p=0.045) and other specialists 
(p=0.048) as more important than non-attenders. 
 
Preferred model of follow-up care: Survivors 
rated paediatric oncologist follow-up 
(mean=2.24, SD=0.72) and medical oncologist 
follow-up highest (mean=2.17, SD=0.69; 
p=0.087). Both these models were rated 
significantly higher than the other three models 
(all p<0.001, apart from medical oncologist 
compared to follow-up by multidisciplinary team 
[MDT]: p=0.031): MDT follow-up (mean=2.07, 
SD=0.73), GP follow-up (mean=1.90, SD=0.84), 
or follow-up by telephone/questionnaire 
(mean=1.06, SD=0.83). Regarding MDT follow-
up, survivors liked being able to contact all 
specialists they needed (mean=2.27, SD=0.81), 
and could be referred to the right specialist 
(mean=2.28, SD=0.77). They did not agree that 
MDT follow-up might be less personal 
(mean=1.50, SD=1.04) or might mean they did 
not know who was responsible for their care 
(mean=1.13, SD=0.96).  
2) Characteristics associated with preferences 
for different models of follow-up care 
In univariable linear regression analyses we 
determined characteristics of survivors with 
different preferences for follow-up models 
(Online Table 2). Attenders rated follow-up by 
medical oncologist higher, and GP or phone-
follow-up lower than non-attenders (Figure 4). 
Higher ratings of  importance of clinical and 
supportive reasons were associated with all 
models: higher endorsement of importance of 
both clinical and supportive reasons were 
associated with lower rating of 
telephone/questionnaire and GP follow-up, and 
higher rating of the other models. Self-reported 
late effects were associated with lower rating of 
GP follow-up and higher rating of MDT follow-
up. Survivors who received chemotherapy rated 
GP and paediatric oncologist follow-up highest 
and survivors undergoing other treatments rated 
them lower. Psychological distress was only 
associated with higher rating of importance 
of?MDT follow-up. Regarding socio-
demographic characteristics, survivors older at 
study and those with higher education rated the 
paediatric oncologist follow-up lower, and 
French speaking survivors rated GP follow-up 
higher. Results of the multivariable linear 
regression remained similarly in the direction of 
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the association. However, fewer characteristics 
remained statistically significant (Table 2). 
 
DISCUSSION 
In our study, approximately half of responding 
survivors continued to attend follow-up. We 
found that clinical reasons for follow-up such as 
checking that cancer has not come back or being 
reassured about their health, were rated higher 
than supportive reasons. Survivors also expected 
competent staff at their follow-up, including 
paediatric or medical oncologists as well as 
general practitioners. Despite the age of these 
survivors (≥18 years) they valued going to the 
children’s hospital for follow-up, but adult 
hospital or GP practice were rated similarly 
highly. Follow-up by paediatric or medical 
oncologist were the preferred follow-up models, 
particularly by those who rated clinical reasons 
for follow-up as very important. 
 
The high endorsement of medical aspects of 
follow-up was similar to previous studies (Eiser 
et al., 1996, Michel et al., 2009, Zebrack et al., 
2004, Earle et al., 2005). In a UK study using the 
same questions, we also found significantly 
higher importance given to clinical reasons than 
supportive reasons (Michel et al., 2009). We also 
found that survivors wanted to discuss clinical 
topics such as their current health, late effects or 
medication, rather than general topics such as 
insurance or work-related issues. Our results also 
support findings of a US study showing that 
survivors wanted to be taken seriously by their 
doctors (Zebrack et al., 2004). 
 
In contrast to UK studies, where GP follow-up 
was rated comparable with 
telephone/questionnaire follow-up (Michel et al., 
2009, Eiser et al., 1996), Swiss survivors rated 
GP follow-up highly, though not as much as 
paediatric or medical oncologist follow-up. The 
high preference for GP follow-up was also found 
in a qualitative study in the USA (Zebrack et al., 
2004); however, survivors ranked follow-up by a 
“primary care physician knowledgeable and 
experienced in working with survivors” (p.849) 
highest. As GPs do not usually care for many 
childhood cancer survivors most will lack the 
required experience. A close collaboration 
between GP and a specialised late effects clinic 
might be a solution to this problem (Oeffinger, 
2003, Singer et al., 2013). A Dutch study 
showed the potential of further education about 
late effects and follow-up care for GPs and that 
GPs were interested in such a programme 
(Blaauwbroek et al., 2007). 
 
Swiss survivors rated paediatric oncologist 
follow-up highest. This is in contrast to a US 
study, where survivors rated a programme 
staffed with a paediatric oncologist and nurse 
practitioner lower than primary care physician 
follow-up (Zebrack et al., 2004). The high 
preference for the paediatric oncologist model in 
Switzerland might be due to the fact that 
survivors get high quality follow-up provided by 
their paediatric oncologist for at least 10 years 
after diagnosis. Therefore, the model describes a 
model with which they are familiar. 
Additionally, in Switzerland we have 9 
specialised centres for paediatric oncology 
across the country, so that this model provides 
appropriate geographical access for most 
survivors.  
 
Both attenders and non-attenders to follow-up 
reported similar preferences for the organisation 
of follow-up. However, attenders valued clinical 
reasons slightly higher than non-attenders. This 
may be one of the reasons why survivors 
continue to attend follow-up while those who 
consider clinical reasons to be less important do 
not. However, this needs to be addressed in 
future work as differences are small. 
 
Expert opinions have often favoured centralised 
follow-up care by specialists (Essig et al., 2012). 
Our results suggest that Swiss survivors are not 
favouring this model; a central specialised late 
effects clinic was rated lowest among the 
provided places. Although, given the size of 
Switzerland, distances to a central clinic would 
be relatively short for most survivors, this 
suggests that there is a preference for follow-up 
to be close to home. Organised transition from 
paediatric to adult oncology clinic seems a 
logical way forward and should contribute to 
optimal follow-up care. 
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A major strength of this study is the involvement 
of a population-based sample including both 
those who attend and those who do not attend 
follow-up care. In addition, we had access to 
established information on diagnosis, treatment 
and relapse from the Swiss Childhood Cancer 
Registry. We also assessed a wide range of 
different characteristics of follow-up care so that 
a detailed picture of survivors’ needs could be 
drawn. 
 
A limitation is that we could not include an 
objective measure of risk for late effects, apart 
from general indicators associated with 
diagnosis, treatment, relapse and second tumour. 
Depending on this risk, different follow-up 
models might be clinically preferable (Wallace 
et al., 2001). For example, survivors with a high 
risk for late effects might require long-term 
specialist care while regular GP visits might be 
sufficient for low-risk survivors. It is not known 
how far survivors agree or not with these 
medical views. Another limitation is the low 
response rate, which might indicate that a large 
number of survivors are not interested in the 
topic of follow-up care or not aware of the 
implications of cancer for their future health. 
 
Follow-up care remains an important aspect of 
long-term survival after childhood cancer, and 
will continue to grow in importance as survivors 
age. It is crucial that long-term follow-up not 
only respects medical guidelines but is organised 
according to survivors’ needs and preferences. 
Our study showed that survivors value clinic-
based follow-up care by specialists, but also 
emphasises the necessity to provide care in 
convenient locations. This needs to be taken into 
account when considering provision of well-
organised long-term follow-up care for adult 
survivors of childhood cancer.  
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Table 1: Sample description: Survivors who responded to the baseline questionnaire only compared to 
survivors who responded to both questionnaires 
  Non-participants   Participants     
  N % N % p* 
Total 440 100.0 314 100.0  
Socio-demographic characteristics      
Sex     <0.001 
Male 252 57.3 138 43.9  
Female 188 42.7 176 56.1  
Age at study     0.283 
≤25 years 292 66.4 220 70.1  
>25 years 148 33.6 94 29.9  
Migration background     0.204 
No migration background 348 79.1 260 82.8  
Migration background 92 20.9 54 17.2  
Language     0.785 
German 324 73.6 234 74.5  
French / Italian 116 26.4 80 25.5  
Partnership      
No partner   186 59.2  
Has partner   128 40.8  
Education      
Vocational training   177 56.4  
Compulsory schooling   69 22.0  
Upper secondary/ university education   68 21.7  
Employment      
Not employed   20 6.4  
Employed   190 60.5  
In education   104 33.1  
Clinical characteristics      
Diagnosis     0.526 
Leukaemia 136 30.9 113 36.0  
Lymphoma 89 20.2 59 18.8  
CNS tumour 71 16.1 36 11.5  
Neuroblastoma 15 3.4 8 2.5  
Retinoblastoma 10 2.3 5 1.6  
Renal tumour 22 5.0 21 6.7  
Hepatic tumour 3 0.7 1 0.3  
Bone tumour 24 5.5 22 7.0  
STS 21 4.8 20 6.4  
Germ cell tumour 20 4.5 9 2.9  
Carcinoma 6 1.4 7 2.2  
Other neoplasm 1 0.2 1 0.3  
LCH 22 5.0 12 3.8  
Treatment     0.030 
Chemotherapy 191 43.4 137 43.6  
Surgery only 77 17.5 32 10.2  
Radiotherapy 135 30.7 114 36.3  
SCT 37 8.4 31 9.9  
Age at diagnosis     0.225 
0-4 years 107 24.3 86 27.4  
5-9 years 134 30.5 78 24.8  
10+ years 199 45.2 150 47.8  
 
Preferences for follow-up care   12 
 
Table 1 continued 
  Non-participants   Participants     
  N % N % p* 
Time since diagnosis     0.102 
16+ years 253 57.5 177 56.4  
11-15 years 144 32.7 91 29.0  
5-10 years 43 9.8 46 14.6  
Relapse      0.309 
No relapse 397 90.2 276 87.9  
Relapse  43 9.8 38 12.1  
Second malignancy     0.580 
None 418 95.0 301 95.9  
Has second malignancy 22 5.0 13 4.1  
Late effects     0.077 
No late effects reported 276 62.7 184 58.6  
Late effects reported 145 33.0 127 40.4  
Psychological distress      
No distress   232 73.9  
Psychological distress   79 25.2  
Follow-up attendance      
Regularly attends follow-up   128 40.8  
Irregularly attends follow-up   22 7.0  
Follow-up completed, visits treating doctor 
for questions   
41 13.1 
 
Follow-up completed, never visit former 
treating doctor   
123 39.2 
 
  mean SD mean SD p# 
Age at study 24.3 4.2 24.1 4.4 0.584 
Age at diagnosis 8.7 4.5 8.9 4.6 0.622 
Time since diagnosis 15.5 3.7 15.2 4.0 0.381 
*p from chi2 tests, #p from two sample t-tests, STS Soft tissue sarcomas, LCH Langerhans cell histiocytosis, SCT 
Stem cell transplantation 
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Table 2: Multivariable linear regression analyses describing characteristics associated with different follow-up model preferences 
Follow-up by Telephone / Questionnaire  General Practitioner  Paediatric Oncologist  Medical Oncologist  Multidisciplinary team 
 Coeff 95% CI p  Coeff 95% CI p  Coeff 95% CI p  Coeff 95% CI p  Coeff 95% CI p 
Intercept 1.91 1.49 2.32   2.54 2.14 2.95   1.91 1.56 2.27   1.55 1.20 1.89   1.52 1.15 1.88  
Age at study                         
<=25 years                         
>25 years 0.07 -0.17 0.32 0.551  -0.05 -0.28 0.19 0.706  -0.18 -0.39 0.03 0.088  -0.17 -0.37 0.04 0.110  0.01 -0.20 0.23 0.907 
Language                         
German                         
French/Italian 0.16 -0.07 0.38 0.171  0.33 0.11 0.55 0.004  -0.12 -0.31 0.08 0.234  -0.04 -0.24 0.15 0.643  -0.08 -0.28 0.12 0.448 
Education                         
Vocational training                         
Compulsory schooling -0.05 -0.28 0.19 0.706  -0.11 -0.34 0.13 0.376  0.24 0.03 0.45 0.024  -0.02 -0.22 0.18 0.836  0.03 -0.19 0.24 0.813 
Upper secondary/ 
university 0.11 -0.15 0.37 0.391  -0.03 -0.28 0.23 0.820  0.02 -0.21 0.24 0.892  0.10 -0.12 0.32 0.351  0.10 -0.13 0.33 0.401 
Treatment                          
Chemotherapy                          
Surgery only -0.02 -0.34 0.31 0.924  -0.29 -0.61 0.03 0.074  -0.43 -0.71 -0.15 0.003  0.00 -0.28 0.27 0.975  -0.15 -0.44 0.14 0.308 
Radiotherapy -0.03 -0.25 0.19 0.775  -0.14 -0.36 0.07 0.188  -0.18 -0.36 0.01 0.066  0.03 -0.16 0.21 0.785  -0.01 -0.21 0.18 0.890 
SCT -0.10 -0.44 0.24 0.551  -0.10 -0.43 0.24 0.563  -0.29 -0.59 0.00 0.049  -0.16 -0.45 0.13 0.271  -0.12 -0.42 0.19 0.451 
Follow-up                         
Follow-up attender                         
Not attending follow-up -0.19 -0.39 0.00 0.055  -0.21 -0.41 -0.02 0.033  0.10 -0.07 0.27 0.259  0.18 0.01 0.35 0.034  0.00 -0.18 0.17 0.984 
Clinical Reasons for follow-up 
(continuous 0-3)                       
Intercept                         
per 1 point increase -0.34 -0.54 -0.14 0.001  -0.04 -0.24 0.16 0.691  0.11 -0.06 0.29 0.197  0.31 0.14 0.48 0.000  0.12 -0.06 0.29 0.198 
Supportive Reasons for follow-up 
(continuous 0-3)                       
Intercept                         
per 1 point increase 0.03 -0.15 0.20 0.750  -0.22 -0.39 -0.05 0.011  0.12 -0.03 0.27 0.111  -0.10 -0.24 0.05 0.195  0.12 -0.04 0.27 0.130 
Psychological distress 
(BSI case)                         
No distress                         
Significant distress -0.14 -0.36 0.07 0.197  -0.07 -0.28 0.15 0.543  0.05 -0.14 0.24 0.628  0.10 -0.08 0.29 0.270  0.16 -0.03 0.36 0.102 
Late effects                         
None                          
Late effects reported -0.01 -0.21 0.19 0.923  -0.09 -0.28 0.11 0.374  -0.07 -0.25 0.10 0.394  -0.03 -0.20 0.14 0.710  0.20 0.03 0.38 0.025 
Coeff: Coefficient, CI: Confidence Interval, SCT: Stem cell transplantation, BSI case: survivor with high distress in the Brief Symptom Inventory (T≥57 on at least 2 scales or the 
Global severity index)   
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FIGURE LEGENDS 
 
Figure 1: Participant and non-participant of the study 
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Figure 2: Reasons for follow-up care (0 not important to 3 very important; mean and 95% 
confidence interval) 
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Figure 3: Importance of different aspects of follow-up (0 not important to 3 very important; 
mean and 95% confidence interval) 
 
Figure 4: Preferences for different models of follow-up care among attenders and non-
attenders to follow-up (mean agreement with 4 items) 
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Non-attenders: reported not attending follow-up regularly or irregularly; attenders: reported 
attending follow-up regularly or irregularly 
Attenders to follow-up 
Non-attenders to follow-up 
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Online Table 1: Differences in preferences for the organisation of follow-up between attenders and non-
attenders to follow-up 
 Non-attenders Attenders  
 Mean 95%CI Mean 95%CI p* 
Reasons for follow-up care      
Clinical reasons (mean score) 2.25 (2.15-2.34) 2.41 (2.32-2.49) 0.014 
Check the cancer has not come back 2.48 (2.35-2.62) 2.57 (2.45-2.69) 0.346 
Get reassurance about health 2.36 (2.24-2.48) 2.51 (2.41-2.62) 0.065 
Help clinic staff learn more about late 
effects of Cancer/treatment 2.10 (1.96-2.24) 2.25 (2.13-2.38) 0.114 
Get the best medical care 2.03 (1.88-2.18) 2.29 (2.17-2.41) 0.009 
Supportive reasons (mean score) 1.54 (1.43-1.65) 1.69 (1.57-1.81) 0.065 
Get information about late effects of 
cancer 2.17 (2.03-2.30) 2.15 (2.02-2.29) 0.888 
Talk to staff who understand what I've 
been through 1.75 (1.59-1.91) 2.05 (1.90-2.21) 0.008 
Get advice about how to keep healthy 1.44 (1.29-1.58) 1.56 (1.41-1.71) 0.228 
Receive psychological support 1.23 (1.07-1.39) 1.38 (1.21-1.54) 0.218 
Get advice about everyday things like 
insurance 1.12 (0.96-1.27) 1.30 (1.14-1.47) 0.105 
What is important during follow-up?      
Competent staff 2.74 (2.67-2.82) 2.74 (2.66-2.82) 0.945 
Be taken seriously 2.70 (2.62-2.77) 2.70 (2.62-2.78) 0.938 
Relationship quality 2.49 (2.39-2.59) 2.53 (2.43-2.63) 0.619 
Insurance reimbursement 2.48 (2.37-2.58) 2.53 (2.41-2.65) 0.473 
Doctor continuity 2.34 (2.22-2.45) 2.48 (2.36-2.61) 0.093 
No long waiting 2.08 (1.95-2.21) 1.90 (1.76-2.04) 0.063 
Regular appointments 1.71 (1.58-1.84) 2.05 (1.92-2.18) <0.001 
Short consultation 1.65 (1.51-1.79) 1.56 (1.42-1.70) 0.400 
Nurse continuity 1.39 (1.24-1.53) 1.48 (1.33-1.63) 0.383 
Meet survivors 0.90 (0.77-1.04) 0.87 (0.74-1.00) 0.759 
What should be included in follow-up?    
Medical follow-up      
Cancer has not come back 2.73 (2.64-2.82) 2.83 (2.75-2.90) 0.110 
Screen for late effects 2.64 (2.55-2.73) 2.70 (2.62-2.78) 0.324 
Info on potential late effects 2.62 (2.53-2.70) 2.65 (2.57-2.74) 0.548 
Other medical FU 1.78 (1.26-2.30) 1.83 (1.21-2.45) 0.902 
General follow-up      
Risk for my children 2.23 (2.11-2.36) 2.21 (2.08-2.35) 0.858 
Psychological counselling 1.42 (1.29-1.56) 1.50 (1.34-1.65) 0.476 
Alternative medicine 1.26 (1.12-1.40) 1.43 (1.28-1.58) 0.093 
Sexuality 1.22 (1.09-1.35) 1.28 (1.15-1.40) 0.555 
Education / Job 0.91 (0.77-1.05) 1.28 (1.12-1.43) 0.001 
Exchange with other survivors 0.91 (0.77-1.06) 0.99 (0.86-1.12) 0.465 
Other offers 0.76 (0.10-1.43) 0.54 (-0.14-1.22) 0.621 
Spirituality 0.35 (0.25-0.45) 0.49 (0.38-0.60) 0.076 
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Online Table 1 continued 
 Non-attenders Attenders  
 Mean 95%CI Mean 95%CI p* 
What medical and non-medical specialists should be involved in follow-up? 
Paediatric Oncologist 2.33 (2.18-2.47) 2.19 (2.02-2.36) 0.221 
General practitioner 2.13 (1.98-2.27) 2.07 (1.91-2.23) 0.596 
Medical Oncologist 1.98 (1.82-2.14) 2.17 (2.01-2.33) 0.101 
Fertility counselling 1.51 (1.34-1.68) 1.45 (1.28-1.62) 0.647 
Gynaecologist 1.20 (1.03-1.37) 1.38 (1.19-1.56) 0.157 
Psychologist/Psychiatrist 1.19 (1.04-1.35) 1.20 (1.04-1.37) 0.935 
Radiotherapies 1.15 (1.00-1.30) 1.00 (0.84-1.16) 0.162 
Specialist nurse 1.12 (0.97-1.28) 1.14 (0.99-1.30) 0.867 
Endocrinologist 1.09 (0.94-1.24) 1.32 (1.15-1.50) 0.045 
Geneticist 1.03 (0.88-1.19) 0.90 (0.74-1.06) 0.237 
Physiotherapist 0.98 (0.84-1.12) 0.99 (0.85-1.14) 0.907 
Nutritional counselling 0.96 (0.81-1.10) 1.03 (0.88-1.18) 0.484 
Insurance counselling 0.90 (0.75-1.04) 0.88 (0.73-1.03) 0.871 
Social worker 0.70 (0.58-0.82) 0.78 (0.64-0.93) 0.386 
Career counselling 0.66 (0.53-0.78) 0.74 (0.59-0.88) 0.397 
Other specialist 0.33 (-0.05-0.71) 1.11 (0.43-1.78) 0.048 
Where would you like to go for follow-up?    
Follow-up at general practitioner 1.94 (1.78-2.10) 1.76 (1.60-1.92) 0.109 
Follow-up at children's hospital 1.93 (1.76-2.10) 1.96 (1.77-2.14) 0.831 
Follow-up at adult hospital 1.92 (1.78-2.07) 1.79 (1.62-1.97) 0.249 
Follow-up at specialised late effect clinic 1.29 (1.12-1.46) 1.19 (1.02-1.36) 0.428 
95%CI: 95% confidence interval  
* p from t-tests for comparison between groups 
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Online Table 2: Univariable linear regression analyses describing characteristics associated with different follow-up model preferences 
Follow-up by Telephone / Questionnaire  General Practitioner  Paediatric Oncologist  Medical Oncologist  Multidisciplinary team 
 Coeff 95% CI p  Coeff 95% CI p  Coeff 95% CI p  Coeff 95% CI p  Coeff 95% CI p 
Total 1.06 0.97 1.15   1.90 1.81 1.99   2.24 2.16 2.32   2.17 2.09 2.25   2.07 1.99 2.15  
Sex    0.527     0.709     0.792     0.086     0.095 
Male 1.09 0.96 1.23   1.88 1.74 2.02   2.23 2.11 2.35   2.09 1.98 2.21   1.99 1.87 2.11  
Female -0.06 -0.25 0.13   0.04 -0.15 0.22   0.02 -0.14 0.18   0.14 -0.02 0.29   0.14 -0.02 0.30  
Age at study    0.306     0.684     0.001     0.119     0.297 
<=25 years 1.03 0.92 1.14   1.91 1.80 2.02   2.33 2.24 2.43   2.21 2.12 2.30   2.04 1.94 2.14  
>25 years 0.10 -0.10 0.31   -0.04 -0.25 0.16   -0.30 -0.47 -0.13   -0.13 -0.30 0.03   0.09 -0.08 0.27  
Parent or child migration 
background    0.425     0.816     0.387     0.997     0.599 
no migration background 1.04 0.94 1.15   1.90 1.80 2.01   2.26 2.17 2.35   2.17 2.08 2.26   2.06 1.97 2.15  
migration background 0.10 -0.15 0.34   -0.03 -0.28 0.22   -0.09 -0.31 0.12   0.00 -0.21 0.21   0.06 -0.16 0.27  
Language    0.231     0.003     0.723     0.773     0.972 
German 1.03 0.92 1.14   1.82 1.71 1.92   2.25 2.16 2.34   2.18 2.09 2.27   2.07 1.97 2.16  
French 0.13 -0.08 0.34   0.32 0.11 0.53   -0.03 -0.22 0.15   -0.03 -0.20 0.15   0.00 -0.19 0.19  
Partner    0.268  0.00 0.00 0.00 0.188     0.351     0.497     0.317 
No 1.10 0.98 1.22   1.95 1.83 2.07   2.21 2.11 2.32   2.15 2.05 2.25   2.03 1.93 2.14  
Yes -0.11 -0.29 0.08   -0.13 -0.32 0.06   0.08 -0.09 0.24   0.05 -0.10 0.21   0.08 -0.08 0.25  
Education    0.243     0.284     0.001     0.948     0.334 
Vocational training 1.05 0.92 1.17   1.95 1.83 2.07   2.20 2.10 2.31   2.17 2.07 2.28   2.02 1.91 2.13  
Compulsory schooling -0.08 -0.31 0.15   -0.19 -0.42 0.04   0.31 0.11 0.51   0.01 -0.19 0.21   0.09 -0.12 0.29  
Upper secondary/ university  0.15 -0.08 0.38   -0.05 -0.28 0.19   -0.13 -0.33 0.07   -0.03 -0.22 0.17   0.15 -0.06 0.36  
Employment     0.599     0.117     0.845     0.112     0.152 
not employed 1.23 0.86 1.59   1.59 1.22 1.95   2.21 1.88 2.54   1.91 1.60 2.22   1.76 1.43 2.09  
employed -0.19 -0.58 0.19   0.37 -0.01 0.76   0.02 -0.32 0.36   0.32 -0.01 0.64   0.31 -0.04 0.65  
in education -0.15 -0.54 0.25   0.26 -0.14 0.66   0.07 -0.29 0.42   0.21 -0.13 0.55   0.35 0.00 0.71  
Clinical characteristics                         
Diagnosis     0.434     0.247     0.068     0.241     0.827 
Leukaemias 1.01 0.85 1.16   1.94 1.78 2.09   2.30 2.17 2.43   2.12 1.99 2.25   2.05 1.91 2.19  
Lymphomas -0.04 -0.30 0.23   0.06 -0.20 0.32   -0.03 -0.25 0.20   0.10 -0.12 0.32   0.02 -0.21 0.26  
CNS tumours 0.07 -0.24 0.38   -0.28 -0.60 0.03   -0.36 -0.63 -0.09   -0.11 -0.38 0.16   -0.06 -0.35 0.22  
Other 0.15 -0.07 0.38   -0.05 -0.27 0.18   -0.04 -0.23 0.16   0.13 -0.05 0.32   0.06 -0.13 0.26  
Treatment    0.412     0.034     0.006     0.958     0.699 
Chemotherapy 1.11 0.97 1.25   2.04 1.90 2.18   2.40 2.28 2.52   2.18 2.06 2.30   2.08 1.96 2.20  
Surgery only 0.05 -0.27 0.37   -0.42 -0.74 -0.10   -0.40 -0.68 -0.13   -0.03 -0.30 0.24   -0.12 -0.41 0.17  
Radiotherapy -0.08 -0.29 0.12   -0.22 -0.43 -0.01   -0.24 -0.42 -0.06   0.01 -0.17 0.18   0.03 -0.16 0.21  
SCT -0.24 -0.57 0.08   -0.19 -0.52 0.13   -0.25 -0.53 0.03   -0.06 -0.34 0.21   -0.10 -0.38 0.19  
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Follow-up by Telephone / Questionnaire  General Practitioner  Paediatric Oncologist  Medical Oncologist  Multidisciplinary team 
 Coeff 95% CI p  Coeff 95% CI p  Coeff 95% CI p  Coeff 95% CI p  Coeff 95% CI p 
Age at diagnosis    0.665     0.819     0.132     0.174     0.731 
0-4 years 1.06 0.89 1.24   1.93 1.76 2.11   2.37 2.21 2.52   2.10 1.95 2.26   2.02 1.86 2.17  
5-9 years 0.07 -0.19 0.32   -0.01 -0.27 0.24   -0.22 -0.44 0.00   -0.01 -0.23 0.20   0.05 -0.17 0.28  
10+ years -0.04 -0.26 0.18   -0.07 -0.29 0.16   -0.14 -0.33 0.05   0.14 -0.05 0.33   0.08 -0.12 0.28  
Time since diagnosis     0.446     0.970     0.068     0.062     0.301 
16+ years 1.11 0.99 1.24   1.91 1.78 2.03   2.16 2.05 2.27   2.10 2.00 2.21   2.02 1.91 2.13  
11-15 years -0.13 -0.34 0.08   -0.03 -0.24 0.19   0.19 0.01 0.38   0.09 -0.08 0.27   0.15 -0.04 0.33  
5-10 years -0.10 -0.37 0.17   -0.01 -0.29 0.26   0.19 -0.05 0.42   0.27 0.04 0.49   0.02 -0.22 0.26  
Relapse     0.602     0.783     0.633     0.291     0.891 
No relapse 1.05 0.95 1.15   1.89 1.80 1.99   2.25 2.16 2.34   2.19 2.10 2.27   2.07 1.98 2.16  
Relapse  0.07 -0.21 0.36   0.04 -0.25 0.33   -0.06 -0.31 0.19   -0.13 -0.36 0.11   -0.02 -0.27 0.23  
Second tumour    0.852     0.882     0.254     0.299     0.959 
None  1.06 0.97 1.16   1.90 1.81 2.00   2.25 2.17 2.34   2.16 2.08 2.24   2.07 1.98 2.15  
Second tumour -0.04 -0.51 0.42   -0.04 -0.50 0.43   -0.23 -0.64 0.17   0.20 -0.18 0.59   -0.01 -0.42 0.40  
Follow-up    0.003     0.000     0.183     0.014     0.557 
Follow-up attender 1.20 1.07 1.32   2.06 1.93 2.19   2.19 2.08 2.30   2.08 1.97 2.18   2.04 1.93 2.16  
Not attending follow-up -0.28 -.46 0.10   -0.34 -.52 -0.16   0.11 -0.05 0.27   0.19 0.04 0.35   0.05 -0.12 0.21  
Clinical Reasons for follow-
up (linear 0-3)    0.000  0.00   0.023     0.001     0.000     0.019 
Intercept 1.90 1.52 2.28   2.33 1.94 2.71   1.70 1.36 2.03   1.55 1.23 1.86   1.67 1.33 2.01  
per 1 point increase -0.36 -0.52 -0.20   -0.19 -0.35 -0.03   0.24 0.10 0.37   0.27 0.14 0.40   0.17 0.03 0.31  
Supportive Reasons for 
follow-up (linear 0-3)    0.017     0.001     0.002     0.199     0.002 
Intercept 1.33 1.09 1.56   2.24 2.02 2.47   1.95 1.75 2.15   2.05 1.86 2.25   1.78 1.58 1.98  
per 1 point increase -0.16 -0.29 -0.03   -0.22 -0.35 -0.09   0.18 0.07 0.30   0.07 -0.04 0.18   0.18 0.07 0.29  
Psychological distress (BSI 
case)    0.155     0.202     0.706     0.690     0.028 
No distress 1.11 1.00 1.21   1.93 1.82 2.04   2.23 2.14 2.32   2.16 2.07 2.25   2.02 1.93 2.12  
Significant distress -0.15 -0.37 0.06   -0.14 -0.35 0.08   0.04 -0.15 0.22   0.04 -0.14 0.21   0.21 0.02 0.40  
Late effects    0.584     0.038     0.214     0.411     0.007 
None  1.09 0.97 1.21   1.98 1.86 2.10   2.29 2.19 2.40   2.20 2.10 2.30   1.98 1.87 2.08  
Late effects reported -0.05 -0.24 0.14   -0.20 -.38 -0.01   -0.10 -0.27 0.06   -0.07 -0.23 0.09   0.23 0.06 0.39  
Coeff: Coefficient, CI: Confidence Interval, CNS: Central nervous system, SCT: Stem cell transplantation, BSI case: survivor with high distress in 
the Brief Symptom Inventory (T≥57 on at least 2 scales or the Global severity index)  
 
 
